Cited by 1,249Cancer Immunotherapy and BiomarkersChromatin Remodeling and CancerRenal cell carcinoma treatment

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Open access

Miao, Diana, Margolis, Claire A., Gao, Wenhua, Voss, Martin H., Li, Wei, Martini, Dylan J., Norton, Craig, Bossé, Dominick, Wankowicz, Stephanie M., Cullen, Dana, Horak, Christine, Wind-Rotolo, Megan, Tracy, Adam, Giannakis, Marios, Hodi, Frank Stephen, Drake, Charles G., Ball, Mark W., Allaf, Mohamad E., Snyder, Alexandra, Hellmann, Matthew D., Ho, Thai, Motzer, Robert J., Signoretti, Sabina, Kaelin, William G., Choueiri, Toni K., Van Allen, Eliezer M.·2018·Science

DOI 10.1126/science.aan5951PMC PMC6035749

Open this paper in CoChat — free account

Abstract

SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.aan5951

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658

Show all 57 references

Sorted by citations

Items 801–900 of 1,001

Berberine restrained proliferation, invasion, and migration by targeting the glycogen synthase kinase 3β/β-catenin pathway in lung adenocarcinoma cells
Wangmu, T., Li, C., Han, G., & Yi, P. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000070 · Cited by 5
Wirkmechanismen, neue Angriffspunkte und potentielle Biomarker bei moderner Immuntherapie
Bedke, J., Stühler, V., Todenhöfer, T., & Stenzl, A. (2018) · Der Urologe · doi:10.1007/s00120-018-0787-z · Cited by 6
RETRACTED ARTICLE: Comprehensive characterization of tumor mutation burden in clear cell renal cell carcinoma based on the three independent cohorts
Huang, J., Li, Z., Fu, L., Lin, D., Wang, C., Wang, X., & Zhang, L. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03299-3 · Cited by 5
Retracted
Leveraging Automation toward Development of a High-Throughput Gene Expression Profiling Platform
Chen, J., Futran, A. S., Crithary, A., Li, S., Wolicki, A., Fogarty, K. E., Baldick, J., Chase, P. S., Arey, B. J., & Lippy, J. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220956593 · Cited by 5
Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses
Chehrazi‐Raffle, A., Malhotra, J., Salgia, S. K., Favorito, C., Hsu, J., Wu, H., & Pal, S. K. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00423 · Cited by 5
Stem‐cell based, machine learning approach for optimizing natural killer cell‐based personalized immunotherapy for high‐grade ovarian cancer
Esmail, S., & Danter, W. R. (2021) · FEBS Journal · doi:10.1111/febs.16214 · Cited by 5
External Validation of the Prognostic Value of an Immune-Associated Gene Panel for Clear Cell Renal Cell Carcinomas
Xie, Z., Wu, L., Hua, S., Zhang, Y., Shi, F., Chen, M., Zhao, S., Liu, Z., Liu, M., & Jiang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.794840 · Cited by 5
PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma
Saiga, K., Ohe, C., Yoshida, T., Ohsugi, H., Ikeda, J., Atsumi, N., Noda, Y., Yasukochi, Y., Higasa, K., Taniguchi, H., et al. (2022) · Cancers · doi:10.3390/cancers14041062 · Cited by 5
NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma
Wei, S., Xing, J., Lu, K., Wang, K., & Yu, W. (2023) · Hereditas · doi:10.1186/s41065-023-00289-6 · Cited by 5
The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature
Ventriglia, J., Passarelli, A. M., Pisano, C., Cecere, S. C., Rossetti, S., Feroce, F., Forte, M., Casartelli, C., Tambaro, R., Pignata, S., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104036 · Cited by 5
PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer.
Santos, M., Lanillos, J., Caleiras, E. J., Valdivia, C., Roldán‐Romero, J. M., Laínez, N., Puente, J., Beuselinck, B., Oudard, S. M., Zucman‐Rossi, J., et al. (2023) · PubMed Central · Cited by 5
SWI/SNF chromatin remodelers in prostate cancer progression
Ordonez‐Rubiano, S. C., Strohmier, B. P., Sood, S., & Dykhuizen, E. C. (2024) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2023.1337345 · Cited by 5
TUSC3 as a potential biomarker for prognosis in clear cell renal cell carcinoma
Yan, Y., Chen, Z., Liao, Y., & Zhou, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10161 · Cited by 5
Impact des signatures moléculaires sur le choix du traitement systémique du cancer du rein métastatique
Simonaggio, A., Epaillard, N., Elaidi, R., Sun, C., Moreira, M., Oudard, S. M., & Vano, Y. A. (2020) · Bulletin du Cancer · doi:10.1016/s0007-4551(20)30275-7 · Cited by 5
miR-758-3p Inhibits Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma and Predicts Favorable Prognosis
Yao, W., & Liu, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s261882 · Cited by 5
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicityPreprint
Brodeur, M. N., Dopeso, H., Zhu, Y., Longhini, A. L. F., Gazzo, A. M., Sun, S., Koche, R. P., Qu, R., Hamard, P.-J., Bykov, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.08.552544 · Cited by 5
The T cell receptor β chain repertoire of tumor infiltrating lymphocytes improves neoantigen prediction and prioritizationPreprint
Pham, T. M. Q., Nguyễn, T. N., Nguyen, B. Q. T., Tran, T. P. D., Pham, N. M. D., Nguyen, H. T. P., Ho, T. K. C., Nguyen, D. V. L., Nguyen, H. T., Tran, D. H., et al. (2024) · eLife · doi:10.7554/elife.94658 · Cited by 5
Self-citation
Single-cell epigenetic profiling reveals an interferon response-high program associated with BAP1 deficiency in kidney cancerPreprint
Camp, S. Y., He, M. X., Cuoco, M. S., Saad, E., Pimenta, E. M., Meli, K., Bakouny, Z., Labaki, C., Titchen, B. M., Kang, Y. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.15.623837 · Cited by 5
Self-citation
Robust identification of perturbed cell types in single-cell RNA-seq data
Nicol, P. B., Paulson, D., Qian, G., Liu, X. S., Irizarry, R., & Sahu, A. D. (2023) · doi:10.1101/2023.05.06.539326 · Cited by 33
Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis
Gu, Z., Deng, E., Ai, J., Wu, F., Su, Q., & Yu, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02052-x · Cited by 4
A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
Chae, Y. K., Othus, M. K. D., Patel, S. P., Aljumaily, R. M., Win, K. Z., Pejovic, T., Thomas, S. S., Robinson, W. R., Kim, H. S., Chung, L. I., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.70020 · Cited by 5
Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma
Koh, Y., Kato, T., Yamamichi, G., Tomiyama, E., Matsushita, M., Hatano, K., Kawashima, A., Nonomura, N., & Uemura, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-05697-4 · Cited by 4
Prognostic value of metal-based ferroptosis and cuproptosis genes and score in lower grade gliomas
Saddozai, U. A. K., Lü, Z., Dong, S., Khawar, M. B., Fan, Z., Cai, L., Guo, X., Akbar, M. U., Khattak, S., Sun, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1608077 · Cited by 5
Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and BAP1 loss
Camp, S. Y., He, M. X., Cuoco, M. S., Garza, A., Xirenayi, S., Bakouny, Z., Saad, E., Masri, J. E., Pimenta, E. M., Meli, K., et al. (2026) · Science Advances · doi:10.1126/sciadv.adv5457 · Cited by 9
Self-citation
Determinants of pancreatic tropism in metastatic renal cell carcinoma
Xu, H., Kapur, P., Christie, A., Nielsen, A. W., Perny, A., Brandenburg, O., Small, C., Miyata, J., Zhong, H., Roberts, C., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.195195 · Cited by 4
Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma
Zhang, Z., Liu, Y., Xi, P., Nie, Y., Sun, T., & Gong, B. (2023) · Hereditas · doi:10.1186/s41065-023-00262-3 · Cited by 4
Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors
Hoch, C. C., Knoedler, L., Knoedler, S. A., Dezfouli, A. B., Schmidl, B., Trill, A., Douglas, J. E., Adappa, N. D., Stögbauer, F., & Wollenberg, B. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01506-9 · Cited by 4
SHC1 serves as a prognostic and immunological biomarker in clear cell renal cell carcinoma: a comprehensive bioinformatics and experimental analysis
Guo, Z., Cai, C., Zhou, K., Song, L., Wang, X., Chen, D., Weng, G., & Huang, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-70897-3 · Cited by 4
Super-high tumor mutational burden predicts complete remission following immunotherapy: from Peto’s paradox to druggable cancer hallmark
Zheng, M. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010486 · Cited by 5
Tumor aneuploidy as a prognostic and predictive biomarker in immune checkpoint blockade
Huang, D., Spurr, L. F., Weichselbaum, R. R., & Pitroda, S. P. (2025) · Nature Genetics · doi:10.1038/s41588-025-02226-x · Cited by 4
Clinical Application of In‐House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital
Takaoka, H., Terai, H., Nakamura, K., Mizuno, T., Kawano, R., Emoto, K., Kurebayashi, Y., Takada, N., Hamabe, K., Horie, K., et al. (2025) · Cancer Science · doi:10.1111/cas.70168 · Cited by 4
Insight into the significance of CD8 + tumor‐infiltrating lymphocytes in squamous cell lung cancer
Shiomi, K., Ichinoe, M., Ushiwata, A., Eshima, K., Nagashio, R., Hayashi, S., Sonoda, D., Kondo, Y., Maruyama, R., Mikubo, M., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15187 · Cited by 3
RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma
Wang, J., Zhang, S., Wang, Y., Zhu, Y., Xu, X., & Guo, J. (2024) · BMC Urology · doi:10.1186/s12894-023-01356-w · Cited by 4
Multidimensional comprehensive and integrated analysis of the potential function of TMEM25 in renal clear cell carcinoma with low expression status
Xi, P., Zhang, Z., Liu, Y., Nie, Y., Gong, B., Liu, J. T., Huang, H., Liu, Z., Sun, T., & Xie, W. (2024) · Aging · doi:10.18632/aging.205372 · Cited by 4
Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution
Momoi, Y., Kumagai, S., & Nishikawa, H. (2025) · International Immunology · doi:10.1093/intimm/dxaf020 · Cited by 5
Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study
Ishihara, H., Kondo, T., Takagi, T., Tachibana, H., Fukuda, H., Yoshida, K., Iizuka, J., Kobayashi, H., & Tanabe, K. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0591-0 · Cited by 4
Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets
Monette, A., Morou, A., Al-Banna, N., Rousseau, L., Lattouf, J., Rahmati, S., Tokár, T., Routy, J., Cailhier, J., Kaufmann, D., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125301 · Cited by 4
DNA methylation as predictive marker of response to immunotherapy?
Heller, G. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00696-3 · Cited by 4
Predicting prognosis and immunotherapeutic response of clear cell renal cell carcinoma
Wang, J., Tu, W., Qiu, J., & Wang, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.984080 · Cited by 4
Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma
Xu, J., Chen, X., Chen, Y., Wang, Q., Jin, Y., & Zhao, H. (2022) · Genetics Research · doi:10.1155/2022/8422339 · Cited by 4
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
Rosellini, M., Marchetti, A., Tassinari, E., Nuvola, G., Rizzo, A., Santoni, M., Mollica, V., & Massari, F. (2022) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2022.2156786 · Cited by 4
Exploration of 68Ga-labelled prostate-specific membrane antigen-11 PET/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma
Wang, B., Deng, Y., Xu, Q., Gao, J., Shen, H., He, X., Ding, Q., Wang, F., & Guo, H. (2023) · Clinical Radiology · doi:10.1016/j.crad.2023.01.003 · Cited by 4
NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma
Hu, C., Lin, W., Zhao, K., Tian, G., Xiangquan, K., Luo, G., Wolf, D. A., & Cheng, Y. (2023) · iScience · doi:10.1016/j.isci.2023.106531 · Cited by 6
Gene set enrichment analysis identifies immune subtypes of kidney renal clear cell carcinoma with significantly different molecular and clinical properties
Chen, Z., Cao, W., Luo, J., Abdelrahman, Z., Lu, Q., Wang, H., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1191365 · Cited by 4
The categorizations of vasculogenic mimicry in clear cell renal cell carcinoma unveil inherent connections with clinical and immune features
Geng, B., Liu, W., Wang, J., Zhang, W. Y., Li, Z., Zhang, N., Hou, W., Zhao, E., Li, X., & You, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1333507 · Cited by 4
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis
Rosellini, M., Mollica, V., Marchetti, A., Coluccelli, S., Giunchi, F., Tassinari, E., Ricci, C., Fiorentino, M., Tallini, G., de Biase, D., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155142 · Cited by 4
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Geurts, B. S., Zeverijn, L. J., Leek, L. V. M., Henegouwen, J. M. V. B., Hoes, L. R., van der Wijngaart, H., van der Noort, V., van de Haar, J., van Ommen‐Nijhof, A., Kok, M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0011 · Cited by 4
Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma
Wells, J. C., Graham, J., Beuselinck, B., Bjarnason, G. A., Donskov, F. N., Hansen, A. R., McKay, R. R., Vaishampayan, U. N., de Velasco, G., Duh, M. S., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.12.007 · Cited by 4
Self-citation
Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy
Hou, Q., & Xu, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_7 · Cited by 4
A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers
Feldman, A. S., Lokeshwar, V. B., & Lin, D. W. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.06.010 · Cited by 4
Subcellular location of source proteins improves prediction of neoantigens for immunotherapy
Castro, A., Kaabinejadian, S., Yari, H., Hildebrand, W. H., Zanetti, M., & Carter, H. K. (2022) · The EMBO Journal · doi:10.15252/embj.2022111071 · Cited by 6
Evolving Role of Genomics in Genitourinary Neoplasms
Devitt, M. E., & Dreicer, R. (2019) · Acta Medica Academica · doi:10.5644/ama2006-124.243 · Cited by 4
PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review
Carneiro, A. P. C. D., Monteiro, F. S. M., & Soares, A. (2021) · Kidney Cancer · doi:10.3233/kca-210111 · Cited by 4
Background, applications and challenges of radiogenomics in genitourinary tumor.
Liu, L., Yi, X., Lü, C., Pang, Y., Zu, X., Chen, M., & Guan, X. (2021) · PubMed Central · Cited by 4
PD-1 blockade-driven anti-tumor CD8 + T cell immunity requires XCR1 + dendritic cellsPreprint
Mao, T., Song, E., & Iwasaki, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.28.066639 · Cited by 5
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 casesPreprint
Li, Y., Yang, X., Zhu, W., Xu, Y., Ma, J., He, C., & Wang, F. (2022) · Research Square · doi:10.21203/rs.3.rs-1724646/v1 · Cited by 4
Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphomaPreprint
Tumuluru, S., Godfrey, J. K., Cooper, A. B., Yu, J., Chen, X., MacNabb, B. W., Venkataraman, G., Zha, Y., Pelzer, B. W., Song, J. Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.17.576100 · Cited by 4
Fumarate activates the IL-6/JAK/STAT3 pathway by inhibiting KDM4C-mediated H3K36me3 demethylation in FH-knockdown renal cancer cells
Xian, J., Pan, X., Kang, Y., Zheng, L., Yin, X., Zhang, M., Wei, Y., Tan, J., Zhang, M., Nie, L., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03195-y · Cited by 3
Chromatin remodeling complexes: architects influencing breast cancer progression
Giovani, O., Eckersley, G. S., Jones, H. R., & Nagarajan, S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1690350 · Cited by 3
B cell–reactive neoantigens boost antitumor immunity
Kim, J. Y., An, J., Kim, S.-Y., Jo, H.-Y., Lee, E. J., Kim, M. J., Cha, H., Lee, S., Park, H., Kim, S. C., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx8303 · Cited by 3
Prognostic Implications of SMARCA4 , ARID1A , and Other BAF Mutations in Non‐Small Cell Lung Cancer
Khalil, A., Collins, M. P., & Quintás‐Cardama, A. (2025) · Cancer Medicine · doi:10.1002/cam4.71442 · Cited by 3
Multidimensional effects of genetic mechanisms in cancer occurrence, development and treatment
Wang, X., Shi, X., Liao, S., Su, T., Gu, Y., Zhang, H., & Li, Z. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.03.006 · Cited by 3
A Vaccine against Cancer: Can There Be a Possible Strategy to Face the Challenge? Possible Targets and Paradoxical Effects
Zefferino, R., & Conese, M. (2023) · Vaccines · doi:10.3390/vaccines11111701 · Cited by 3
STX4 as a potential biomarker for predicting prognosis and guiding clinical treatment decisions in clear cell renal cell carcinoma
Zeng, K., Li, Q., Wang, X., Liu, C., Chen, B., Song, G., Li, B., Liu, B., Gao, X., Zhang, L., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23918 · Cited by 3
Identification of HDAC10 as a candidate oncogene in clear cell renal carcinoma that facilitates tumor proliferation and metastasis
Yang, L., Wei, Q., Chen, X., Yang, Y., Huang, Q., Wang, B., & Ma, X. (2024) · Diagnostic Pathology · doi:10.1186/s13000-024-01493-2 · Cited by 3
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience
Rosellini, M., Mollica, V., Marchetti, A., Coluccelli, S., Giunchi, F., Tassinari, E., Danielli, L., Maloberti, T., Ricci, C., Fiorentino, M., et al. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155964 · Cited by 4
Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance
Peighambari, A., Huang, H., Metzger, P., Adlesic, M., Zodel, K., Schäfer, S., Seidel, P., Braun, L. M., Hülsdünker, J., Melchinger, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04917-1 · Cited by 3
Mapping cancer gene dynamics through state-specific interactions
Real, A. M., Ollé-Monràs, L., & Park, S. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115872 · Cited by 3
High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy
Theodros, D., Murter, B., Sidhom, J.-W., Nirschl, T. R., Clark, D. J., Chen, L., Tam, A. J., Blosser, R. L., Schwen, Z. R., Johnson, M. H., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002049 · Cited by 3
Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
Wang, A., Chu, H., Zheng, J., Jia, Q., & Zhu, B. (2021) · Disease Markers · doi:10.1155/2021/9453692 · Cited by 3
Clear cell renal cell carcinoma with stage IV cavoatrial tumour thrombus extension and rapid metastatic reoccurrence postsurgical treatment with review of current treatment strategies
Gudapati, P., & Abouamara, M. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-248156 · Cited by 3
Pan-cancer analysis reveals signal transducer and activator of transcription (STAT) gene family as biomarkers for prognostic prediction and therapeutic guidance
Cheng, M., Liu, Y., Guo, Y., Li, M., Xian, S., Qin, H., Yang, Y., Qian, W., Tang, J., Lu, Y., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1120500 · Cited by 4
An immune infiltration-related prognostic model of kidney renal clear cell carcinoma with two valuable markers: CAPN12 and MSC
Xia, G., Wu, S. J., & Cui, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1161666 · Cited by 3
The clinicopathological features of BRG1-deficient non-small cell lung cancer and its response to immunotherapy: A single-center retrospective study
Zhang, J., Zhao, R., Xu, H., Dong, L., & Chen, X. (2023) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2023.152192 · Cited by 3
Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates
Lang, F., Sorn, P., Schrörs, B., Weber, D., Krämer, S., Şahin, U., & Löwer, M. (2023) · iScience · doi:10.1016/j.isci.2023.108014 · Cited by 3
Elucidating the role of MICAL1 in pan-cancer using integrated bioinformatics and experimental approaches
Li, C.-X., Xiao, Y., Kong, J., Lai, C., Chen, Z., Li, Z., & Xie, W. (2024) · Cell Adhesion & Migration · doi:10.1080/19336918.2024.2335682 · Cited by 3
Construction of an autophagy-related genes risk model as predicting prognosis: BAG1 suppresses growth of clear cell renal cell carcinoma
Guo, J., Chen, Q., Han, S., Wang, T., Xia, K., Yu, B., Qiu, T., & Zhou, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112737 · Cited by 3
Predicting Resistance to Immunotherapy in Melanoma, Glioblastoma, Renal, Stomach and Bladder Cancers by Machine Learning on Immune Profiles
Mestrallet, G. (2024) · Onco · doi:10.3390/onco4030014 · Cited by 3
Predicting the polybromo-1 (PBRM1) mutation of a clear cell renal cell carcinoma using computed tomography images and KNN classification with random subspace
Ökmen, H. B., Güveniş, A., & Uysal, H. (2019) · Vibroengineering PROCEDIA · doi:10.21595/vp.2019.20931 · Cited by 3
The contemporary role of metastasectomy in the management of metastatic RCC
Feuer, Z. S., Taylor, J. I., & Huang, W. C. W. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.164 · Cited by 4
Assessing Pd-L1 Status in Mrcc Treated with First-Line Immune-Based Combinations: A Meta-Analysis
Rizzo, A., Mollica, V., Santoni, M., & Massari, F. (2022) · Immunotherapy · doi:10.2217/imt-2021-0261 · Cited by 3
Molekulare Prädiktoren in der Immunonkologie
Weichert, W. (2018) · Der Pathologe · doi:10.1007/s00292-018-0508-9 · Cited by 3
The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice
Huang, J. J., & Hsieh, J. J.-D. (2020) · Kidney Cancer · doi:10.3233/kca-200085 · Cited by 2
Germline genomes have a dominant‐heritable contribution to cancer immune evasion and immunotherapy response
Jiang, X., Asad, M., Li, L., Sun, Z., Milanese, J., Liao, B., & Wang, E. (2020) · Quantitative Biology · doi:10.1007/s40484-020-0212-7 · Cited by 3
Personalized Medicine in Oncology
Vanderwalde, A. M. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2820-5 · Cited by 4
Association of ATRX mutations with immunologically active characteristics in patients with MSI-prone tumors.
Ge, Y., Wang, Z., Li, H., Liu, Y., & Wei, P. (2022) · PubMed Central · Cited by 3
Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy
Chen, C., Chen, L., Yang, R., Zhang, J., Shao, P., & Xu, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1118472 · Cited by 3
Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience
Dizman, N., Bergerot, P. G., Bergerot, C. D., Hsu, J., & Pal, S. K. (2019) · Kidney Cancer · doi:10.3233/kca-190056 · Cited by 3
Exploiting the circuit breaker cancer evolution model in human clear cell renal cell carcinoma
Hsieh, J. J.-D., & Cheng, E. H. Y. (2020) · Cell Stress · doi:10.15698/cst2020.08.227 · Cited by 3
BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal MesotheliomaPreprint
Shrestha, R., Nabavi, N., Lin, Y.-Y., Mo, F., Anderson, S., Volik, S., Adomat, H. H., Lin, D., Xue, H., Dong, X., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/243477 · Cited by 3
Recurrent PD-L1 Structural Rearrangements in Natural Killer/T Cell Lymphoma Patients with Complete Response to PD-1 Blockade TherapyPreprint
Lim, J. Q., Tang, T. P. L., Cai, Q., Tan, D. C. L., Nairismägi, M., Laurensia, Y., Chia, B. K. H., Peng, R., Iqbal, J., Huang, D., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/372383 · Cited by 3
Transcriptional heterogeneity in cancer-associated regulatory T cells is predictive of survivalPreprint
Borcherding, N. C., Ahmed, K. K., Voigt, A. P., Vishwakarma, A., Kolb, R. H., Kluz, P., Pandey, G., Gibson-Corley, K. N., Klesney‐Tait, J., Zhu, Y., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/478628 · Cited by 3
Fibroblastic reticular cells predict response to immune checkpoint inhibitorsPreprint
Biasci, D., Thaventhiran, J. E. D., & Tavaré, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.19.955666 · Cited by 3
Cancer-specific associations of driver genes with immunotherapy outcomePreprint
Jun, T. W., Qing, T., Dong, G., Signaevsky, M., Hopkins, J. F., Frampton, G. M., Albacker, L. A., Cordon‐Cardo, C., Samstein, R. M., Pusztai, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.16.155895 · Cited by 3
Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
Demidova, E. V., Ghatalia, P., & Arora, S. (2021) · European Urology · doi:10.1016/j.eururo.2021.10.028 · Cited by 3
neoMS: Attention-based Prediction of MHC-I Epitope PresentationPreprint
Mill, N. A., Bogaert, C., Criekinge, W. V., & Fant, B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.13.491845 · Cited by 3
Integrative multi-omics analysis reveals molecular subtypes and tumor evolution of synovial sarcomaPreprint
Chen, Y., Su, Y., Leo, I. R., Siavelis, I., Zeng, J., Cao, X., Tsagkozis, P., Hesla, A. C., Papakonstantinou, A., Liu, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.09.490894 · Cited by 3
Viewing RCC with a DNA Methylation Lens ENHANCES Understanding of ICI Resistance
Zhou, M., & Kim, W. Y. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3574 · Cited by 3
Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Lee, J. H., Hwang, S., Jee, B., Kim, J., Lee, J., Chung, J. H., Song, W., Sung, H. H., Jeon, H. G., Jeong, B. C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043994 · Cited by 2
TG468: a text graph convolutional network for predicting clinical response to immune checkpoint inhibitor therapy
Wang, K., Shi, J., Tong, X., Qu, N., Kong, X., Ni, S., Xing, J., Li, X., & Zheng, M. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae017 · Cited by 2

Authors: Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., Horak, C., Wind-Rotolo, M., Tracy, A., Giannakis, M., Hodi, F. S., Drake, C. G., Ball, M. W., Allaf, M. E., Snyder, A., Hellmann, M. D., Ho, T., Motzer, R. J., Signoretti, S., Kaelin, W. G., Choueiri, T. K., & Van Allen, E. M.
Affiliations: Broad Institute (US)
Dana-Farber Cancer Institute (US)
Memorial Sloan Kettering Cancer Center (US)
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Bristol-Myers Squibb (United States) (US)
Bristol-Myers Squibb, New York, NY 10154, USA.
Columbia University Irving Medical Center (US)
Johns Hopkins University (US)
Mayo Clinic in Arizona (US)
Howard Hughes Medical Institute (US)
Corresponding author: Choueiri, Toni K.
ORCID: Miao, Diana
Margolis, Claire A.
Gao, Wenhua
Voss, Martin H.
Li, Wei
Martini, Dylan J.
Bossé, Dominick
Wind-Rotolo, Megan
Tracy, Adam
Giannakis, Marios
Hodi, Frank Stephen
Drake, Charles G.
Ball, Mark W.
Allaf, Mohamad E.
Snyder, Alexandra
Hellmann, Matthew D.
Ho, Thai
Motzer, Robert J.
Signoretti, Sabina
Kaelin, William G.
Choueiri, Toni K.
Van Allen, Eliezer M.
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2018-02-16
Volume: 359
Issue: 6377
Pages: 801-806
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.aan5951
PMC: PMC6035749
OpenAlex: W2782183686
Cited by: 1,249
References: 57
Citations by year: 2026: 73 · 2025: 93 · 2024: 153 · 2023: 164 · 2022: 186 · 2021: 195 · 2020: 179 · 2019: 113 · 2018: 89
FWCI: 54.48
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (K08 CA188615, U24CA224316)
Howard Hughes Medical Institute (Medical Research Fellowship)
American Association for Cancer Research (KureIt Grant for Kidney Research)
NIH Office of the Director (P30 CA008748)
Bristol-Myers Squibb (II-ON Consortium)
Dana-Farber Cancer Institute (Loker Pinard Funds for Kidney Cancer Research)
Dana-Farber/Harvard Cancer Center (Kidney SPORE)
BroadNext10
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: clear cell renal cell carcinoma, immune checkpoint inhibitors, SWI/SNF complex, PBRM1 mutation, tumor response prediction, antitumor immunity, interferon-gamma, T cell-mediated killing, metastatic renal cell carcinoma, cancer genomics
MeSH terms: Carcinoma, Renal Cell, Chromosomal Proteins, Non-Histone, Humans, Immunotherapy, Kidney Neoplasms, Mutation, Transcription Factors, Cohort Studies, Gene Expression Profiling, Genomics, Exome, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks